Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Clinical Development Suppliers In Europe
134 companies found
based inBaldham, GERMANY
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ...
Several cancers arise from the lack of DNA mismatch repair (MMR) resulting in the accumulation of thousands of single deletions or insertions at coding microsatellites (MSI-H). These mutations lead to the inactivation of specific proteins and to the ...
based inParis, FRANCE
The Bioprojet company was founded in 1982 under the impetus of Jeanne-Marie Lecomte and Jean-Charles Schwartz, doctors of pharmacy and sciences. From very different backgrounds, Jeanne-Marie Lecomte made her career in the pharmaceutical industry, ...
based inLyon, FRANCE
NOVA is a leading Healthtech company which simulates in silico clinical trials in virtual patient populations for bio-pharma companies with a need to accelerate and de-risk their R&D. With over a decade of experience and multiple commercial projects ...
Explore various regimens (dose, number of administrations per day, time between administrations, duration of treatment). Identify subgroups of optimal responders / theranostic biomarkers. Leverage real-world data to inform clinical trial ...
based inLausanne, SWITZERLAND
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug ...
Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
a monoclonal antibody fragment and CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal. The net effect of CD28 antagonism is down regulating effector T-cells while promoting T-Reg activity. The ...
based inArnhem, NETHERLANDS
Soteria Medical B.V. is a Spin Off from Radboudumc in Nijmegen, The Netherlands. Many years of development and clinical research have resulted in a new approach to perform MRI guided interventions by utilizing a robotic device, which is fully ...
based inEmmendingen, GERMANY
Biomedical technology – developed and manufactured in Germany: inomed is the first choice for medical specialists worldwide. Cost-effective clinical outcomes and patient safety are the highest priorities in today's healthcare environment. Biomedical ...
based inHaifa, ISRAEL
Pluristem Therapeutics Inc. is a clinical-stage regenerative medicine company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, muscle injuries, ...
COVID-19 is caused by infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause clusters of severe respiratory illness associated with the need for intensive care unit (ICU) admission and high mortality. ...
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
Complementary expertise for successful progress at each stage of your development. After the discovery and proof-of-concept phases, the preclinical development of new therapeutic entities is a critical step for the ...
based inWendelsheim, GERMANY
AESKU.GROUP, based in Wendelsheim, Germany, is a research-focused supplier of innovative and efficient products and services for the early detection, diagnosis and prognosis of autoimmune diseases. AESKU.DIAGNOSTICS is a leading manufacturer of ...
based inPraha 10, CZECH REPUBLIC
MEDICEM is a biomedical company researching, developing, manufacturing, and commercializing medical devices with unique, proprietary hydrogels for specific clinical applications. Based in the Czech Republic, MEDICEM leverages a deep and broad ...
In this area, MEDICEM leverages its patented material platform featuring a unique hydrogel designed to expand under pressure. DILAPAN-S is a synthetic osmotic hygroscopic dilator for the uterine cervix made from proprietary anisotropic xerogel. The ...
based inTübingen, GERMANY
Founded in 2015, Atriva Therapeutics is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company ...
The company’s lead drug candidate is the MEK inhibitor zapnometinib. The small molecule, which can be administered orally (tablet), is under advanced clinical development in two severe respiratory viral ...
based inLausanne, SWITZERLAND
Amazentis is an innovative life science company dedicated to employing breakthrough research and clinical science to bring advanced therapeutic nutrition products to life. We employ rigorous science to pioneer the discovery and clinical development ...
based inAllendale, NEW JERSEY (USA)
We are a leading global contract development and manufacturing organization (CDMO) dedicated to the advancement and manufacturing of gene and cell therapy products. Minaris Regenerative Medicine is a leading global contract development and ...
At Minaris Regenerative Medicine, we are committed to bringing together and further developing highly talented, skilled, and dedicated experts with varied backgrounds applicable to gene and cell therapy manufacturing and ...
based inCambridge, MASSACHUSETTS (USA)
Founded in Cambridge, Massachusetts, in 2013, Curelator develops clinical grade, personalized disease management tools for patients and clinicians. Currently, its main platform is N1-Headache, a unique patient engagement platform that delivers ...
based inGranada, SPAIN
Regemat 3D makes available to research and science a technology tailormade designed what born to integrate the advantages of the additive manufacturing with tissue engineering and applied to the regenerative medicine. The personalized configuration ...
based inBresso, ITALY
At BiomimX we develop clinically relevant and fast responsive technology driven solutions tailored made to fit applications in Big Diseases. Integrating 3D cell culture and mechanical stimulation, BiomimX proposes the next generation of beating ...
based inFlintshire, UNITED KINGDOM
Quay Pharma is an independent, privately owned contract development manufacturing organisation (CDMO). Since 2002 we have proudly delivered over 250 successful projects and exercised continued improvement whilst remaining true to our core values. ...
We are extensively involved in developing early clinical formulations and clinical manufacturing of First in Human trials. We can develop a formulation specifically designed to ...
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
Cantrixil is a product candidate in clinical stage being developed for the treatment of ovarian cancer. Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor ...